QLC5513
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 04, 2026
QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Fudan University
New P2 trial • Breast Cancer • Hormone Receptor Negative Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ER • HER-2 • PGR
1 to 1
Of
1
Go to page
1